




RealRate

PHARMACEUTICAL 2013

Anixa Biosciences Inc
Rank 109 of 218



The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 182% points. The greatest weakness of Anixa Biosciences Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 238%, being 18% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	922
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,822
Liabilities, Non-Current	0
Other Assets	4,728
Other Compr. Net Income	0
Other Expenses	139
Other Liabilities	0
Other Net Income	17
Other Revenues	947
Property and Equipment	10
Research and Development	2,212
Selling, General and Administrative Expense	2,866

Output Variable	Value in 1000 USD
Assets	5,661
Liabilities	1,822
Expenses	5,217
Revenues	947
Stockholders Equity	3,838
Net Income	-4,253
Comprehensive Net Income	-4,253
BaseVar	6,832
ECR before Limited Liability	110%
Economic Capital Ratio	238%